PharmaEssentia (TPE:6446) said an independent Data and Safety Monitoring Board recommended continuing its Phase III trial of its drug for pre-fibrotic/early or overt primary myelofibrosis.
The drug, dubbed ropeginterferon alfa-2b (P1101), is being studied in adults under the multinational, multicenter HOPE-PMF trial, according to a Friday filing with the Taiwan bourse.
The company said the study will continue according to its protocol, with the core study expected to be completed in 2027.